T0	KEYPHRASE-NOTYPES 13 22	diagnosis,"the","of "
T1	KEYPHRASE-NOTYPES 26 38	Lyme disease," of","is "
T2	KEYPHRASE-NOTYPES 67 78	individuals," of","tre"
T3	KEYPHRASE-NOTYPES 115 136	antimicrobial therapy,"ded","(Ta"
T4	KEYPHRASE-NOTYPES 138 143	Table,"py ","2) "
T5	KEYPHRASE-NOTYPES 152 171	successful outcomes,"ave"," [2"
T6	KEYPHRASE-NOTYPES 189 214	long-term outcome studies,"ely","of "
T7	KEYPHRASE-NOTYPES 218 236	untreated patients," of","fol"
T8	KEYPHRASE-NOTYPES 285 296	individuals,"ese","to "
T9	KEYPHRASE-NOTYPES 328 335	variety,"f a","of "
T10	KEYPHRASE-NOTYPES 339 362	clinical manifestations," of","con"
T11	KEYPHRASE-NOTYPES 378 394	Lyme borreliosis," to","at "
T12	KEYPHRASE-NOTYPES 403 408	point,"ome","in "
T13	KEYPHRASE-NOTYPES 412 416	time," in","aft"
T14	KEYPHRASE-NOTYPES 427 449	spontaneous resolution,"the","of "
T15	KEYPHRASE-NOTYPES 459 468	EM lesion,"eir"," [4"
T16	KEYPHRASE-NOTYPES 475 492	First line agents,"49]","con"
T17	KEYPHRASE-NOTYPES 517 528	doxycycline,"ven"," am"
T18	KEYPHRASE-NOTYPES 530 541	amoxicillin,"ne,"," an"
T19	KEYPHRASE-NOTYPES 547 564	cefuroxime axetil,"and"," Do"
T20	KEYPHRASE-NOTYPES 566 577	Doxycycline,"il.","has"
T21	KEYPHRASE-NOTYPES 591 600	advantage,"ded","of "
T22	KEYPHRASE-NOTYPES 615 637	antimicrobial activity,"ing","aga"
T23	KEYPHRASE-NOTYPES 649 665	phagocytophilium," A.","in "
T24	KEYPHRASE-NOTYPES 673 678	event,"the","tha"
T25	KEYPHRASE-NOTYPES 684 695	coinfection,"hat","has"
T26	KEYPHRASE-NOTYPES 710 731	Macrolide antibiotics,"ed.","are"
T27	KEYPHRASE-NOTYPES 753 772	second-line choices," be","in "
T28	KEYPHRASE-NOTYPES 787 798	intolerance,"ith","or "
T29	KEYPHRASE-NOTYPES 802 819	contraindications," or","to "
T30	KEYPHRASE-NOTYPES 823 846	beta-lactam medications," to","and"
T31	KEYPHRASE-NOTYPES 851 862	doxycycline,"and"," bu"
T32	KEYPHRASE-NOTYPES 876 903	cautious clinical follow-up,"ire","sin"
T33	KEYPHRASE-NOTYPES 961 973	Historically,"96]"," th"
T34	KEYPHRASE-NOTYPES 979 985	length,"the","of "
T35	KEYPHRASE-NOTYPES 989 998	treatment," of","has"
T36	KEYPHRASE-NOTYPES 1016 1020	days,"21]"," ho"
T37	KEYPHRASE-NOTYPES 1040 1058	available evidence,"tly","sup"
T38	KEYPHRASE-NOTYPES 1083 1091	duration,"the","of "
T39	KEYPHRASE-NOTYPES 1095 1104	treatment," of","wit"
T40	KEYPHRASE-NOTYPES 1110 1121	doxycycline,"ith","to "
T41	KEYPHRASE-NOTYPES 1128 1132	days," 10"," [9"
T42	KEYPHRASE-NOTYPES 1139 1150	Retreatment,"97]","is "
T43	KEYPHRASE-NOTYPES 1190 1201	individuals," as","wit"
T44	KEYPHRASE-NOTYPES 1207 1237	persistent subjective symptoms,"ith"," bu"
T45	KEYPHRASE-NOTYPES 1246 1264	objective findings," no","of "
T46	KEYPHRASE-NOTYPES 1268 1292	ongoing active infection," of","hav"
T47	KEYPHRASE-NOTYPES 1329 1347	additional courses,"rom","of "
T48	KEYPHRASE-NOTYPES 1351 1362	antibiotics," of"," [9"
T49	KEYPHRASE-NOTYPES 1410 1423	cephalosporin,"IV)","ant"
T50	KEYPHRASE-NOTYPES 1436 1447	ceftriaxone,"ic,"," ha"
T51	KEYPHRASE-NOTYPES 1472 1494	antibacterial activity,"tro","aga"
T52	KEYPHRASE-NOTYPES 1503 1504	B,"nst"," bu"
T53	KEYPHRASE-NOTYPES 1537 1559	clinical circumstances,"all","pro"
T54	KEYPHRASE-NOTYPES 1583 1596	clear benefit,"any","ove"
T55	KEYPHRASE-NOTYPES 1606 1609	use,"the","of "
T56	KEYPHRASE-NOTYPES 1613 1629	oral doxycycline," of"," [1"
T57	KEYPHRASE-NOTYPES 1656 1670	4-week courses,", 2","of "
T58	KEYPHRASE-NOTYPES 1674 1697	intravenous ceftriaxone," of","is "
T59	KEYPHRASE-NOTYPES 1745 1753	patients," in","wit"
T60	KEYPHRASE-NOTYPES 1759 1771	Lyme disease,"ith","and"
T61	KEYPHRASE-NOTYPES 1776 1825	unquestionable objective neurologic abnormalities,"and","103"
T62	KEYPHRASE-NOTYPES 1853 1861	patients,"zed","wit"
T63	KEYPHRASE-NOTYPES 1867 1901	high-degree atrioventricular block,"ith","are"
T64	KEYPHRASE-NOTYPES 1929 1952	intravenous ceftriaxone,"ith","and"
T65	KEYPHRASE-NOTYPES 1962 1972	completion,"ith","of "
T66	KEYPHRASE-NOTYPES 1983 2006	21-day treatment course," 14","usi"
T67	KEYPHRASE-NOTYPES 2016 2026	oral agent," an"," [2"
T68	KEYPHRASE-NOTYPES 2033 2042	Placement,"22]","of "
T69	KEYPHRASE-NOTYPES 2048 2075	permanent cardiac pacemaker,"f a","is "
T70	KEYPHRASE-NOTYPES 2117 2122	times," at"," a "
T71	KEYPHRASE-NOTYPES 2151 2169	external pacemaker," or","is "
T72	KEYPHRASE-NOTYPES 2187 2201	Lesser degrees,"104","of "
T73	KEYPHRASE-NOTYPES 2205 2216	heart block," of","(fi"
T74	KEYPHRASE-NOTYPES 2218 2239	first-degree AV block,"ck "," PR"
T75	KEYPHRASE-NOTYPES 2241 2252	PR interval,"ck,","< 3"
T76	KEYPHRASE-NOTYPES 2259 2263	msec,"300"," ca"
T77	KEYPHRASE-NOTYPES 2285 2296	oral agents,"ith","alo"
